Mundipharma EDO GmbH shows strong preclinical activity with its lead compound (EDO-S101) in Multiple Myeloma
15 July 2014 | By Mundipharma EDO GmbH
Mundipharma EDO GmbH is pleased to announce strong preclinical activity in Multiple Myeloma with its lead small molecule compound EDO-S101...